Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Wieder

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Anticancer Research|February 9, 2013
Collagen I provides a survival advantage to MD-1483 head and neck squamous cell carcinoma cells through phosphoinositol 3-kinase signalingErik Cohen, Tara Tendler, Haiyan Lu, et al.
Investigational New Drugs|July 3, 2010
A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancerMargarette Bryan, E Dianne Pulte, Kathleen C Toomey, et al.
American Journal of Clinical Oncology|October 24, 2002
Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomasRobert Wieder, Anna C Pavlick, Margarette Bryan, et al.
Cancer Epidemiology|October 9, 2017
Improving cancer patient emergency room utilization: A New Jersey state assessmentAnthony J Scholer, Omar M Mahmoud, Debopyria Ghosh, et al.
Investigational New Drugs|October 31, 2003
Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignanciesRobert Wieder, Steven C Novick, Bruce W Hollis, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Anticancer Research|February 9, 2013
Collagen I provides a survival advantage to MD-1483 head and neck squamous cell carcinoma cells through phosphoinositol 3-kinase signalingErik Cohen, Tara Tendler, Haiyan Lu, et al.
Investigational New Drugs|July 3, 2010
A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancerMargarette Bryan, E Dianne Pulte, Kathleen C Toomey, et al.
American Journal of Clinical Oncology|October 24, 2002
Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomasRobert Wieder, Anna C Pavlick, Margarette Bryan, et al.
Cancer Epidemiology|October 9, 2017
Improving cancer patient emergency room utilization: A New Jersey state assessmentAnthony J Scholer, Omar M Mahmoud, Debopyria Ghosh, et al.
Investigational New Drugs|October 31, 2003
Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignanciesRobert Wieder, Steven C Novick, Bruce W Hollis, et al.
Pageof 4